Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany.

Autor:	Becker V; Neurologische Praxis Eppendorf, Hamburg, Germany., Heeschen V; Novartis Pharma GmbH, Nuremberg, Germany., Schuh K; Novartis Pharma GmbH, Nuremberg, Germany., Schieb H; Novartis Pharma GmbH, Nuremberg, Germany., Ziemssen T; Center of Clinical Neuroscience, University Clinic Carl Gustav Carus Dresden, Fetscherstraße 74, 01307 Dresden, Germany.
Jazyk:	angličtina
Zdroj:	Therapeutic advances in neurological disorders [Ther Adv Neurol Disord] 2018 Jan 23; Vol. 11, pp. 1756285617748845. Date of Electronic Publication: 2018 Jan 23 (Print Publication: 2018).
DOI:	10.1177/1756285617748845
Abstrakt:	Background: As patients with multiple sclerosis (MS) require lifelong treatment, optimization of therapy with respect to efficacy and safety is needed to limit long-term disease progression. Patients with MS also need a range of health-related services. Satisfaction with these as well as treatment is clinically relevant because satisfied patients are more likely to adhere to therapy. The aim of this study was to determine the status of patient satisfaction and of healthcare services in 70 specialized MS centres in Germany. Methods: In 2011, patients with MS responded to a questionnaire, which solicited clinical and demographic information, as well as patients' perceptions of their overall situation and their satisfaction with treatment. Results: Of 2791 patients surveyed, 81.9% had relapsing-remitting MS with mild disability [mean (standard deviation) Expanded Disability Status Scale score: 2.6 (1.8)]. Disease activity data were collected from 2205 patients, of whom 57.6% had remained relapse-free during the preceding 12 months. However, 38.9% had experienced one or more relapses, most of whom (67.3%) while receiving immunomodulatory treatment. About one-third of the patients indicated that they were more dissatisfied with their overall situation compared with the time before diagnosis. However, many patients (58.3%) were satisfied with their existing medication. Overall, 72.8% of patients would prefer oral to injectable treatments, assuming there was no difference in their efficacy. Conclusions: A substantial proportion of patients experienced breakthrough disease on treatment and may potentially benefit from a change of therapy. Although largely satisfied with treatment, most patients with MS would choose oral over injectable treatments. Competing Interests: Conflict of interest statement: Veit Becker has received reimbursements for participation in scientific advisory boards and speaker honoraria from Merck, Biogen, Novartis Pharma AG, Genzyme, Sanofi. He received research support from Novartis Pharma AG, Merck and Teva. Volker Heeschen, Katrin Schuh and Heinke Schieb are employees of Novartis Pharma GmbH. Tjalf Ziemssen has received reimbursements for participation in scientific advisory boards from Bayer Healthcare, Biogen Idec, Novartis Pharma AG, Merck Serono, Teva, Genzyme, and Synthon. He has also received speaker honorarium from Bayer Healthcare, Biogen Idec, Genzyme, Merck Sharp & Dohme, GlaxoSmithKline, Novartis Pharma AG, Teva, Sanofi Aventis, and Almirall. He has also received research support from Bayer Healthcare, Biogen Idec, Genzyme, Novartis Pharma AG, Teva, and Sanofi Aventis.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu